Pushing Therapeutic Boundaries in CLL
This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
Wednesday, December 16 at 1:30 PM EST
How does measurable residual disease (MRD) impact treatment decisions and practice patterns for patients with CLL? Learn from experts, including Dr. John Pagel, member of CLL Society’s Board and Medical Advisory Board.
Related posts